Understanding Avatrombopag Dosage
Avapag 20 mg is identified on this website as a product containing avatrombopag, an oral thrombopoietin receptor agonist (TPO-RA). Avatrombopag works by stimulating platelet production in the bone marrow.
The appropriate dosage depends on the medical condition being treated, the patient’s platelet count, treatment response, other medicines and individual health factors.
Avatrombopag is used in specific adults with thrombocytopenia associated with chronic liver disease who are scheduled to undergo a medical procedure, and in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.
Important product-specific limitation: The strength stated for Avapag is 20 mg. The exact approved dosage instructions, formulation, manufacturer and regulatory status of Avapag must be confirmed from its own packaging and official product documentation. The dosing information below describes the reference avatrombopag prescribing regimen and must not be treated as a personal prescription or confirmation of Avapag’s authorization.
Reference Avatrombopag Dosage Regimens
The following regimens are described in the U.S. prescribing information for the reference product Doptelet tablets. They are included to explain how avatrombopag dosing may differ according to the indication. They are not a dosing instruction for Avapag 20 mg.
Dosage for Thrombocytopenia Associated With Chronic Liver Disease
For adults with chronic liver disease who are scheduled to undergo a medical procedure, the reference tablet regimen is based on the platelet count measured before treatment.
| Platelet count before treatment | Reference daily dose | Treatment duration |
|---|---|---|
| Below 40 × 10⁹/L | 60 mg | 5 consecutive days |
| 40 to below 50 × 10⁹/L | 40 mg | 5 consecutive days |
Treatment with the reference product begins 10–13 days before the scheduled procedure. The procedure is generally planned 5–8 days after the final dose.
The platelet count should be checked before treatment and again on the day of the procedure. This regimen is designed to increase platelet counts sufficiently for the planned procedure; it is not intended to normalize platelet counts.
Dosage for Chronic Immune Thrombocytopenia (ITP) in Adults
For adults with chronic ITP who have not responded adequately to previous treatment, the reference tablet prescribing information gives an initial dose of:
– 20 mg once daily with food.
The treating clinician adjusts the dose or dosing frequency according to platelet-count response. The reference product’s maximum recommended adult dose is 40 mg per day.
The aim is to maintain a platelet count of at least 50 × 10⁹/L when needed to reduce bleeding risk, using the lowest effective dose. The treatment is not intended to produce a normal platelet count.
Do not use these reference regimens to decide how many Avapag tablets to take. The appropriate instructions for Avapag must be confirmed from its own approved product information and by the prescribing clinician.
How to Take Avatrombopag Tablets
For the reference avatrombopag tablet product, the prescribing information gives the following general administration instructions:
- Take the tablet orally according to the prescribed schedule.
- Take it with food.
- Follow the prescribed dose and frequency carefully.
- Swallow the tablet as directed by the product instructions.
- Do not change the dose based on symptoms or an individual platelet-count result without medical advice.
- Do not take additional tablets to compensate for a dose you think was insufficient.
The exact administration instructions for Avapag should be checked against its own packaging and patient information leaflet.
Should Avatrombopag Be Taken Before or After Food?
The U.S. prescribing information for the reference Doptelet tablet instructs patients to take the medicine with food.
Food instructions should not be assumed to be identical for every product or formulation without checking its official product information. Follow the instructions supplied with the specific medicine prescribed to you.
When and How Often Is Avatrombopag Taken?
The frequency depends on the condition being treated.
- Chronic ITP: The reference adult tablet regimen starts with once-daily administration, with later adjustments based on platelet counts and other medicines.
- Chronic liver disease before a procedure: The reference tablet regimen uses a five-day course timed around the planned procedure.
These are different treatment schedules. A person receiving avatrombopag for one indication should not follow the schedule intended for another indication.
What Happens If You Miss a Dose?
Missed-dose instructions can differ according to the reason for treatment and the product’s prescribing information.
For the reference Doptelet product:
- For chronic ITP, the patient information advises taking a missed dose when remembered and returning to the usual schedule, without taking two doses at the same time.
- For treatment before a scheduled procedure, the patient should contact the healthcare professional for instructions if a dose is missed.
Do not double a dose. If you are unsure what to do, contact the prescribing clinician or pharmacist.
What If Too Much Avatrombopag Is Taken?
Taking more avatrombopag than prescribed may increase the risk of unwanted effects, including an excessive rise in platelet count and possible thrombotic complications.
If an overdose is suspected:
- Contact a healthcare professional or local poison-information service immediately.
- Seek urgent medical assessment if symptoms develop or a large amount may have been taken.
- Keep the medicine packaging available so the healthcare team can identify the product and strength.
- Do not wait for symptoms before seeking advice.
Do not attempt to manage a suspected overdose by changing future doses yourself.
Platelet Count Monitoring During Treatment
Platelet monitoring is an essential part of avatrombopag treatment. The medicine affects platelet production, so clinicians use blood-test results to evaluate its effect and guide dose adjustments.
Monitoring for Chronic Liver Disease
For the reference product, platelet counts are checked:
- Before starting treatment.
- On the day of the scheduled procedure.
These tests help determine whether the platelet count has increased sufficiently for the planned procedure.
Monitoring for Chronic ITP
For the reference adult ITP regimen, the prescribing information recommends:
- Checking platelet counts before treatment.
- Monitoring weekly after treatment begins until a stable platelet count of at least 50 × 10⁹/L is achieved.
- Monitoring monthly after the platelet count becomes stable.
- Continuing weekly monitoring for at least four weeks after treatment is discontinued.
The clinician may require additional tests depending on the patient’s medical condition and response.
Important Precautions Before Taking Avatrombopag
Before treatment, inform your healthcare professional about your medical history and all medicines you take.
Important considerations include:
History of blood clots: Avatrombopag belongs to a class of medicines associated with thrombotic and thromboembolic complications. Tell your doctor if you have previously experienced deep vein thrombosis, pulmonary embolism, stroke or another blood-clotting condition.
Liver disease: Patients with chronic liver disease require careful assessment because their underlying condition may affect both bleeding and clotting risks.
Other medical conditions: Inform your doctor about any significant medical condition, including inherited or acquired conditions that increase the risk of blood clots.
Pregnancy: Discuss pregnancy or plans to become pregnant with your healthcare professional. The reference product prescribing information warns of potential fetal harm.
Breastfeeding: The reference product information advises against breastfeeding during treatment.
Other medicines: Provide a complete list of prescription medicines, nonprescription medicines, vitamins and supplements.
Drug Interactions That May Affect Dosage
Certain medicines can change avatrombopag exposure in the body.
The reference prescribing information identifies interactions involving enzymes known as CYP2C9 and CYP3A4.
Examples of medicines that may require particular attention include:
- Certain antifungal medicines.
- Some antibiotic medicines.
- Certain medicines used to treat seizures.
- Other medicines that affect CYP2C9 or CYP3A4 activity.
The effect depends on the specific medicine and whether it inhibits or induces the relevant enzymes.
A healthcare professional should review the complete medication list before treatment and determine whether any dosage adjustment or additional monitoring is necessary.
Do not stop another prescribed medicine or change avatrombopag dosing without medical advice.
Possible Side Effects During Treatment
Avatrombopag may cause side effects. The reported reactions differ according to the condition being treated.
For the reference product, commonly reported reactions in adults with chronic liver disease include:
- Fever.
- Abdominal pain.
- Nausea.
- Headache.
- Fatigue.
- Peripheral edema.
In adults treated for chronic ITP, reported reactions include:
- Headache.
- Fatigue.
- Bruising.
- Nosebleeds.
- Upper respiratory tract infections.
- Joint pain.
- Gum bleeding.
- Small red or purple skin spots.
- Nasopharyngitis.
Not everyone experiences these effects. Contact a healthcare professional if side effects are persistent, worsening or concerning.
Serious Warning: Blood Clots
Thrombotic and thromboembolic complications are an important safety concern with thrombopoietin receptor agonists.
Seek urgent medical assessment for symptoms that could indicate a blood clot, such as:
- Sudden chest pain.
- Difficulty breathing.
- Sudden swelling or pain in one leg.
- Sudden weakness or numbness.
- Sudden difficulty speaking.
- Sudden changes in vision.
These symptoms require prompt medical attention.
Who Should Not Adjust the Dose Independently?
Patients should never independently increase, decrease or discontinue avatrombopag because of a perceived change in symptoms or platelet count.
Dose decisions require consideration of:
- The original treatment indication.
- Current platelet count.
- Previous platelet-count results.
- Response to treatment.
- Risk factors for thrombosis.
- Other medicines being taken.
- The prescribed product’s official instructions.
A higher platelet count does not automatically mean better treatment. The goal is an appropriate platelet response while minimizing the risk of complications.
Frequently Asked Questions About Avapag Dosage
What is the strength of Avapag?
Avapag is identified on this website as a 20 mg product containing avatrombopag. Its exact product formulation and approved instructions should be confirmed from its packaging and official documentation.
Is Avapag 20 mg the same as a 20 mg daily dose?
No. Product strength and prescribed daily dosage are different concepts. A 20 mg tablet describes the amount of active ingredient in one tablet, while the prescribed daily dose depends on the treatment plan.
How often is avatrombopag taken?
The reference adult ITP tablet regimen begins with once-daily administration. For chronic liver disease before a procedure, the reference regimen is a five-day course. The appropriate schedule depends on the indication and prescribing instructions.
Should avatrombopag be taken with food?
The U.S. prescribing information for reference Doptelet tablets instructs patients to take the medicine with food. Check the official instructions for the specific product being used.
Can I take two 20 mg tablets together?
Do not take two tablets together unless your prescribing clinician has specifically instructed you to do so. The correct dose depends on the indication, platelet count and individual treatment plan.
Can I stop avatrombopag when my platelet count improves?
Do not stop treatment without medical advice. Your clinician will determine whether treatment should continue, be adjusted or be discontinued.
What should I do if I forget a dose?
Follow the missed-dose instructions for your specific product and treatment indication. Do not take a double dose to compensate.
Does avatrombopag normalize platelet counts?
Treatment is not intended to normalize platelet counts. The reference prescribing information recommends using the lowest effective dose to achieve the treatment goal.
Do I need regular blood tests?
Yes. Platelet-count monitoring is important during treatment. The timing and frequency depend on the indication and your response.
Can I change my dose based on a blood test?
No. Platelet-count results should be reviewed by your healthcare professional, who can decide whether a dose adjustment is appropriate.
Important Dosage Disclaimer
The dosage information on this page is educational and is based on the U.S. prescribing information for the reference avatrombopag product, Doptelet. It is not confirmation that Avapag has the same approved instructions, formulation, manufacturer or regulatory authorization.
Avapag 20 mg should only be used according to verified product instructions and the directions of a qualified healthcare professional.
Never start, stop or change a prescription medicine without appropriate medical guidance.